Premature termination codons appear in different genes and diseases, yet they create the same translation-level failure: protein synthesis stops before completion. KritRNA is building around that shared mechanism with engineered suppressor tRNAs designed to help the ribosome continue.
Disease names differ. The molecular event can be the same: a premature stop prevents production of the full-length protein.
A nonsense mutation changes a coding triplet into UAA, UAG or UGA before the intended end of the message.
The ribosome terminates early, producing a shortened protein or no useful protein output.
The transcript may also be reduced through nonsense-mediated mRNA decay, further lowering protein production.
Many disease labels. One interrupted instruction.
An engineered suppressor tRNA can recognise a selected premature stop and deliver an amino acid, allowing the ribosome to continue toward a full-length protein. This is a distinct therapeutic modality: it operates at the level of translation, works with the cell’s own mRNA and does not require permanent DNA editing.
Suppressor tRNAs offer a combination of programmability, molecular specificity and cross-disease platform potential that is unusual among therapeutic modalities.
Suppressor tRNAs act on the mRNA message during protein synthesis rather than permanently editing genomic DNA.
Candidate tRNAs can be designed around the selected premature stop, intended amino acid and local sequence environment.
Different diseases can share the same molecular failure class, allowing knowledge to compound across programmes.
The goal is to recover full-length protein from the endogenous transcript already produced by the cell.
A successful candidate must satisfy several coupled biological constraints at once. KritRNA evaluates each design as a complete molecule in a specific transcript and cellular context.
Recognise the selected premature stop in its local sequence context.
Preserve the tRNA architecture required for processing and function.
Retain the identity elements needed for charging by the intended aminoacyl-tRNA synthetase.
Reach the ribosomal A site and compete with eRF1/eRF3 at the premature stop.
Limit unacceptable readthrough at normal termination codons.
Function under the tRNA abundance, modification and stress state of the relevant cell.
Insert an amino acid compatible with restoration of useful protein structure or function.
Survive maturation, expression and delivery constraints without losing activity.
The modality has credible scientific precedent. KritRNA’s programmes now focus on designing better candidates, testing them rigorously and building a repeatable platform around the biology.
KritRNA combines candidate design with translation-system modelling so every suppressor tRNA is evaluated as both a molecule and a systems-level intervention.
